Sarepta Therapeutics, Inc.
SRPT· Nasdaq
SRPTSarepta Therapeutics, Inc.
Filed Mar 2, 2026 · 10-K · 61 days after period end · 0001193125-26-084144
| Metric | Q4 2025 | Q4 2024 | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures |
|---|---|---|---|---|
| Revenue | $442.93M | $658.41M | $463.53M | $235.93M |
| Net Income | -$412.23M | $159.05M | $45.66M | -$109.24M |
| EPS Diluted | -$3.93 | $1.50 | — | — |
Sarepta Therapeutics, Inc. · CIK 873303 · Engraved from SEC EDGAR
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
ended Dec 31, 2025 · filed Mar 2, 2026 · 61 d after period end
